MedPath

Muscle Recovery After Critical Illness

Recruiting
Conditions
Critical Illness
ICU Acquired Weakness
Post Intensive Care Unit Syndrome
Muscle Weakness
Registration Number
NCT05537298
Lead Sponsor
Kirby Mayer
Brief Summary

The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness:

1. to examine the recovery of muscle and physical function in ICU survivors through longitudinal assessments

2. to investigate the underlying cellular markers and mechanisms of muscle recovery in ICU survivors

3. to determine which cellular markers contribute to physical disability in ICU survivors up to 1 year after hospital admission

Detailed Description

Patients surviving critical illness develop significant impairments in skeletal muscle, commonly referred to as ICU-acquired weakness (ICUAW)\[8-10\]. It is estimated that up to 70-80% of patients admitted to ICU will develop some degree of neuromuscular dysfunction, weakness, myopathy or atrophy \[11,12\]. ICUAW encompasses muscle impairments that develop as a direct result of admission for critical illness\[13\] and is an independent predictor of mortality and long-term functional impairments\[14-19\]. Interventions to mitigate muscle deficits and improve physical function are a critical area of rehabilitation because of the high prevalence of short- and long-term impairments. ICU survivorship is particularly important as roughly 6 million Americans will survive an acute admission to the ICU this year alone.\[24-26\] Survivors of critical illnesses such as sepsis, viral-illnesses including coronaviruses, and acute respiratory failure (ARF) have reduced quality of life, lost wages from inability to return to work and increased caregiver and healthcare burden for years after hospital discharge.\[27-31\] Impairments in skeletal muscle are known contributors to physical disability and specifically prevent the performance of simple daily life activities like standing up from a chair. However, very little is known about cellular mechanisms leading to muscle and physical dysfunction in patients surviving critical illness during recovery. These gaps in knowledge are significant because identifying the phenotypes and underlying cellular mechanisms that lead to impaired muscle and physical function will facilitate the development of pharmacologic and non-pharmacologic interventions to mitigate or reverse disability. From a scientific perspective, this proposal is noteworthy because it will be the first to assess muscle protein synthesis rates in combination with cellular phenotypes, muscle strength, and physical function in patients recovering from an ICU admission. Studying muscle at the cellular level and integrating that knowledge with physical function will help improve our understanding of why certain patients fail to recover.

Elucidating cellular mechanisms during recovery phase will provide the framework to develop interventions in subsequent studies. We will assess measures of muscle and physical function in the first year of recovery to establish why some patients have restored function, yet others have sustained disability. Improved classification of muscle dysfunction and physical function enables future studies to employ a targeted approach instead of the historical rehabilitation approach of one-size-fits-all. Specifically, the cellular findings will lead to development of novel interventions specifically designed for the underlying mechanisms, while identification of the recovery trajectories will enhance clinicians' ability to implement interventions to patients with the greatest need.

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
206
Inclusion Criteria
  • adult (>18 y/o)
  • admission for sepsis or acute respiratory failure with at least 72 hour stay in ICU
Exclusion Criteria
  • acute or chronic neurologic condition
  • acute or chronic orthopedic condition preventing strength/functional testing
  • patients who were not ambulatory prior to ICU admission
  • patients not expected to survive ~6months after admission

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Muscle strengththe change from baseline to 12-months

lower-extremity muscle strength

Muscle powerthe change from baseline to 12-months

lower-extremity muscle power (unilateral leg-press)

Mitochondrial functionthe change from baseline to 12-months

muscle mitochondrial respirometry

Physical functionthe change from baseline to 12-months

Short Physical Performance Battery

Secondary Outcome Measures
NameTimeMethod
Physical activitythe change from baseline to 12-months

actigraphy

functional mobilitythe change from baseline to 12-months

timed-up and go test

Muscle morphology #1the change from baseline to 12-months

myofiber size

Cardiopulmonary endurance / exercise capacitythe change from baseline to 12-months

6-minute walk test

Muscle morphology #2the change from baseline to 12-months

myofiber type

self-reported health-related quality of lifethe change from baseline to 12-months

EuroQol-5Domains (EQ-5D) visual analog scale is a self-report of quality of life (0-100) with higher scores indicating a better perception of quality of life

Trial Locations

Locations (3)

Oklahoma Medical Research Foundation

🇺🇸

Oklahoma City, Oklahoma, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

University of Kentucky

🇺🇸

Lexington, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath